123 related articles for article (PubMed ID: 35341646)
1. Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy).
Fano V; Crielesi A; Coviello E; Fabiani M; Salvatore Miglietta A; Colaiocco G; Moretti I; Pasqua C; Vivaldi F; De Angelis G; Cerimele M
Vaccine; 2022 Apr; 40(18):2540-2545. PubMed ID: 35341646
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of the Comirnaty (BNT162b2, BioNTech/Pfizer) vaccine in preventing SARS-CoV-2 infection among healthcare workers, Treviso province, Veneto region, Italy, 27 December 2020 to 24 March 2021.
Fabiani M; Ramigni M; Gobbetto V; Mateo-Urdiales A; Pezzotti P; Piovesan C
Euro Surveill; 2021 Apr; 26(17):. PubMed ID: 33928898
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.
Machado A; Kislaya I; Rodrigues AP; Sequeira D; Lima J; Cruz C; Leite PP; Matias Dias C; Nunes B
PLoS One; 2022; 17(9):e0274008. PubMed ID: 36099273
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Post-Vaccination Response between mRNA and Vector Vaccines against SARS-CoV-2 in Terms of Humoral Response after Six Months of Observation.
Slomka S; Zieba P; Rosiak O; Piekarska A
Vaccines (Basel); 2023 Oct; 11(10):. PubMed ID: 37897027
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
6. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.
Starrfelt J; Danielsen AS; Buanes EA; Juvet LK; Lyngstad TM; Rø GØI; Veneti L; Watle SV; Meijerink H
BMC Med; 2022 Sep; 20(1):278. PubMed ID: 36050718
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study.
Fano V; Coviello E; Consonni D; Agresta A; Orsini N; Crielesi A; Miglietta AS; Pasqua C; Vairo F; Vivaldi F; De Angelis G; Colaiocco G; Fabiani M
Expert Rev Vaccines; 2022 Aug; 21(8):1147-1157. PubMed ID: 35584901
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.
Milevoj Kopcinovic L; Unic A; Nikolac Gabaj N; Miler M; Vrtaric A; Bozovic M; Stefanovic M
Lab Med; 2024 Mar; 55(2):162-168. PubMed ID: 37294928
[TBL] [Abstract][Full Text] [Related]
9. A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022.
Guibert N; Trepat K; Pozzetto B; Josset L; Fassier JB; Allatif O; Saker K; Brengel-Pesce K; Walzer T; Vanhems P; Trouillet-Assant S;
Euro Surveill; 2023 Apr; 28(15):. PubMed ID: 37052679
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccine Hesitancy and Early Adverse Events Reported in a Cohort of 7,881 Italian Physicians.
Monami M; Gori D; Guaraldi F; Montalti M; Nreu B; Burioni R; Mannucci E
Ann Ig; 2022; 34(4):344-357. PubMed ID: 34821928
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.
Kissling E; Hooiveld M; Martínez-Baz I; Mazagatos C; William N; Vilcu AM; Kooijman MN; Ilić M; Domegan L; Machado A; de Lusignan S; Lazar M; Meijer A; Brytting M; Casado I; Larrauri A; Murray JK; Behillil S; de Gier B; Mlinarić I; O'Donnell J; Rodrigues AP; Tsang R; Timnea O; de Lange M; Riess M; Castilla J; Pozo F; Hamilton M; Falchi A; Knol MJ; Kurečić Filipović S; Dunford L; Guiomar R; Cogdale J; Cherciu C; Jansen T; Enkirch T; Basile L; Connell J; Gomez V; Sandonis Martín V; Bacci S; Rose AM; Pastore Celentano L; Valenciano M; ;
Euro Surveill; 2022 May; 27(21):. PubMed ID: 35620997
[TBL] [Abstract][Full Text] [Related]
13. Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study).
Risco-Risco C; Martínez-Urbistondo D; Suárez Del Villar R; Ayerbe García-Monzón L; Pérez-Rubio A; Barberán-López J; Andaluz-Ojeda D; Villares Fernández P
Rev Esp Quimioter; 2023 Aug; 36(4):400-407. PubMed ID: 37119130
[TBL] [Abstract][Full Text] [Related]
14. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021.
Ireland G; Whitaker H; Ladhani SN; Baawuah F; Subbarao S; Linley E; Warrener L; O'Brien M; Whillock C; Martin O; Moss P; Ramsay ME; Amirthalingam G; Brown KE
Euro Surveill; 2022 Jan; 27(1):. PubMed ID: 34991777
[TBL] [Abstract][Full Text] [Related]
15. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and effectiveness of BNT162b2 COVID-19 vaccine in a cohort of healthcare workers in Milan (Lombardy Region, Northern Italy).
Consonni D; Lombardi A; Mangioni D; Bono P; Oggioni M; Uceda Renteria S; Valzano A; Bordini L; Nava CD; Tiwana N; Gentiloni Silverj F; Castaldi S; Rognoni M; Cavalieri D'Oro L; Carugno M; Luisetti G; Riboldi L; Ceriotti F; Bandera A; Gori A; Pesatori AC
Epidemiol Prev; 2022; 46(4):250-258. PubMed ID: 36259341
[TBL] [Abstract][Full Text] [Related]
18. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
[TBL] [Abstract][Full Text] [Related]
19. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
20. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
